AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
AR029903A1
(es)
|
2000-04-05 |
2003-07-23 |
Schering Corp |
Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
|
CN1432022A
(zh)
|
2000-04-19 |
2003-07-23 |
先灵公司 |
含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
CZ2003195A3
(cs)
|
2000-07-21 |
2003-04-16 |
Schering Corporation |
Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
|
US7012066B2
(en)
|
2000-07-21 |
2006-03-14 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
MXPA03005219A
(es)
|
2000-12-12 |
2003-09-25 |
Schering Corp |
Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
|
ATE349463T1
(de)
*
|
2001-07-11 |
2007-01-15 |
Vertex Pharma |
Verbrückte bizyklische serinproteaseinhibitoren
|
NZ531681A
(en)
*
|
2001-10-24 |
2007-05-31 |
Vertex Pharma |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
PE20030857A1
(es)
*
|
2002-01-23 |
2003-10-25 |
Schering Corp |
Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
NZ561851A
(en)
|
2002-04-11 |
2009-05-31 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
|
ES2315568T3
(es)
|
2002-05-20 |
2009-04-01 |
Bristol-Myers Squibb Company |
Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
|
EP1506172B1
(de)
|
2002-05-20 |
2011-03-30 |
Bristol-Myers Squibb Company |
Inhibitoren des hepatitis-c-virus
|
ATE481106T1
(de)
|
2002-05-20 |
2010-10-15 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
DE602004029866D1
(de)
|
2003-03-05 |
2010-12-16 |
Boehringer Ingelheim Pharma |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
EP1601685A1
(de)
|
2003-03-05 |
2005-12-07 |
Boehringer Ingelheim International GmbH |
Hepatitis-c-inhibitierende verbindungen
|
KR100971347B1
(ko)
*
|
2003-03-08 |
2010-07-20 |
주식회사유한양행 |
씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
|
WO2004092203A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Boehringer Ingelheim International, Gmbh |
Process for preparing macrocyclic compounds
|
US7176208B2
(en)
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
PT1654261E
(pt)
|
2003-05-21 |
2008-01-18 |
Boehringer Ingelheim Int |
Compostos inibidores da hepatite c
|
CA2536570A1
(en)
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
TW201127828A
(en)
|
2003-09-05 |
2011-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
DE602004031645D1
(de)
|
2003-09-22 |
2011-04-14 |
Boehringer Ingelheim Pharma |
Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
|
KR20060085248A
(ko)
|
2003-09-26 |
2006-07-26 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 세린 프로테아제의마크로사이클릭 억제제
|
DK1680137T3
(da)
|
2003-10-14 |
2013-02-18 |
Hoffmann La Roche |
Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
|
KR20060120166A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1689770A1
(de)
*
|
2003-11-20 |
2006-08-16 |
Schering Corporation |
Depeptidisierte inhibitoren der hepatitis-c-virus-ns3-protease
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2007513200A
(ja)
|
2003-12-08 |
2007-05-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
超臨界流体処理によるルテニウム副生物の除去
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
AR048401A1
(es)
|
2004-01-30 |
2006-04-26 |
Medivir Ab |
Inhibidores de la serina-proteasa ns3 del vhc
|
US7582770B2
(en)
|
2004-02-20 |
2009-09-01 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
PT1719773E
(pt)
|
2004-02-24 |
2009-06-03 |
Japan Tobacco Inc |
Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
TWI314927B
(en)
|
2004-02-27 |
2009-09-21 |
Schering Corporatio |
Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
RU2006134002A
(ru)
|
2004-02-27 |
2008-04-10 |
Шеринг Корпорейшн (US) |
Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
|
ATE438622T1
(de)
|
2004-02-27 |
2009-08-15 |
Schering Corp |
3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
WO2005087721A2
(en)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
Compounds as inhibitors of hepatitis c virus ns3 serine protease
|
TW200536528A
(en)
|
2004-02-27 |
2005-11-16 |
Schering Corp |
Novel inhibitors of hepatitis C virus NS3 protease
|
RU2006136084A
(ru)
|
2004-03-15 |
2008-04-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Способ получения микроциклических соединений
|
BRPI0509467A
(pt)
*
|
2004-03-30 |
2007-09-11 |
Intermune Inc |
compostos macrocìclicos como inibidores de replicação viral
|
WO2005113581A1
(en)
|
2004-05-20 |
2005-12-01 |
Schering Corporation |
Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
|
JP5156374B2
(ja)
|
2004-05-25 |
2013-03-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
非環式hcvプロテアーゼインヒビターの調製方法
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
EP1771454B1
(de)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Peptidanaloga als hepatitis c-hemmer
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
WO2006030892A1
(ja)
*
|
2004-09-17 |
2006-03-23 |
Nippon Shinyaku Co., Ltd. |
複素環化合物の製造方法
|
CN102160891A
(zh)
|
2004-10-01 |
2011-08-24 |
威特克斯医药股份有限公司 |
Hcv ns3-ns4a蛋白酶抑制
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101160317B
(zh)
|
2005-03-08 |
2013-03-27 |
贝林格尔·英格海姆国际有限公司 |
制备大环化合物的方法
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AP2007004245A0
(en)
|
2005-05-13 |
2007-12-31 |
Virochem Pharma Inc |
Compounds and methods for the treatment or prevention of flavivirus infections
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
EP1915378A4
(de)
|
2005-08-12 |
2009-07-22 |
Boehringer Ingelheim Int |
Viren-polymerasehemmer
|
CA2621360C
(en)
|
2005-09-09 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Ring-closing metathesis process for the preparation of macrocyclic peptides
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
BRPI0712021A2
(pt)
|
2006-05-23 |
2012-01-03 |
Irm Llc |
composto e composiÇÕes como inibidores da protease ativadora de canal
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(de)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
|
RU2009109355A
(ru)
|
2006-08-17 |
2010-09-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Ингибиторы вырусной полимеразы
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ576780A
(en)
|
2006-11-15 |
2011-12-22 |
Virochem Pharma Inc |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2162431B1
(de)
|
2007-06-29 |
2017-06-07 |
Gilead Sciences, Inc. |
Antivirale verbindungen
|
US8513186B2
(en)
|
2007-06-29 |
2013-08-20 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US8242140B2
(en)
|
2007-08-03 |
2012-08-14 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
WO2009076173A2
(en)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide hcv serine protease inhibitors
|
US8476257B2
(en)
|
2007-12-19 |
2013-07-02 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
PE20110388A1
(es)
|
2008-09-16 |
2011-07-01 |
Boehringer Ingelheim Int |
Formas cristalinas de un derivado de peptido como inhibidores de hcv
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP3025727A1
(de)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Verfahren zur behandlung von lebererkrankungen
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
SG172848A1
(en)
|
2009-01-07 |
2011-08-29 |
Scynexis Inc |
Cyclosporine derivative for use in the treatment of hcv and hiv infection
|
EP2408449A4
(de)
|
2009-03-18 |
2012-08-08 |
Univ Leland Stanford Junior |
Verfahren und zusammensetzungen zur behandlung von flaviviridae-virusinfektionen
|
US8377962B2
(en)
|
2009-04-08 |
2013-02-19 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
EP2429568B1
(de)
|
2009-05-13 |
2016-08-17 |
Enanta Pharmaceuticals, Inc. |
Makrozyklische verbindungen als hepatitis-c-virus-hemmer
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
JP5476859B2
(ja)
*
|
2009-08-25 |
2014-04-23 |
住友化学株式会社 |
光学活性な1−アミノ−2−エテニルシクロプロパン−1−カルボン酸エチルまたはその酸付加塩の製造方法、およびその製造方法に用いられる中間体
|
JP2013512247A
(ja)
|
2009-11-25 |
2013-04-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用
|
EP2515902A1
(de)
|
2009-12-24 |
2012-10-31 |
Vertex Pharmaceuticals Incorporated |
Analoga zur behandlung oder vorbeugung von flavivirus-infektionen
|
AU2011209051B2
(en)
|
2010-01-27 |
2015-01-15 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
EP2550268A1
(de)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analoga zur behandlung oder vorbeugung von flavivirus-infektionen
|
EP2550278A1
(de)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analoga zur behandlung oder vorbeugung von flavivirus-infektionen
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
CA2794145A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
WO2011159826A2
(en)
|
2010-06-15 |
2011-12-22 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
EP2585448A1
(de)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Verbindungen und verfahren zur behandlung oder vorbeugung von flavivirus-infektionen
|
UY33473A
(es)
|
2010-06-28 |
2012-01-31 |
Vertex Pharma |
Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
|
AU2011292040A1
(en)
|
2010-08-17 |
2013-03-07 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of Flaviviridae viral infections
|
PE20140015A1
(es)
|
2010-09-21 |
2014-02-16 |
Enanta Pharm Inc |
Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
|
BR112013008510A2
(pt)
|
2010-10-08 |
2016-07-05 |
Novartis Ag |
vitamina e formulações de inibidores de sulfamida ns3
|
AU2011352145A1
(en)
|
2010-12-30 |
2013-07-18 |
Abbvie Inc. |
Phenanthridine macrocyclic hepatitis C serine protease inhibitors
|
MX2013007677A
(es)
|
2010-12-30 |
2013-07-30 |
Abbvie Inc |
Inhibidores macrociclicos de serina proteasa de hepatitis.
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012121068A1
(ja)
*
|
2011-03-10 |
2012-09-13 |
住友化学株式会社 |
光学活性1-アミノ-2-ビニルシクロプロパンカルボン酸エステルの製造方法
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012171332A1
(zh)
|
2011-06-16 |
2012-12-20 |
爱博新药研发(上海)有限公司 |
抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016492A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Thiophene compounds
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
MX349036B
(es)
|
2011-12-06 |
2017-07-07 |
Univ Leland Stanford Junior |
Metodos y composiciones para tratar enfermedades virales.
|
WO2013142157A1
(en)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
MX360452B
(es)
|
2012-10-19 |
2018-11-01 |
Bristol Myers Squibb Co |
Inhibidores del virus de la hepatitis c.
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014071007A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9598433B2
(en)
|
2012-11-02 |
2017-03-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(en)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014134251A1
(en)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
WO2014137869A1
(en)
|
2013-03-07 |
2014-09-12 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014138374A1
(en)
|
2013-03-08 |
2014-09-12 |
Boehringer Ingelheim International Gmbh |
Oral combination therapy for treating hcv infection in specific patient sub-population
|
EP3089757A1
(de)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Feste antivirale darreichungsformen
|
EP2899207A1
(de)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
Neues Verfahren zum Testen von HCV-Proteasehemmung
|
JP2022510407A
(ja)
|
2018-12-04 |
2022-01-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
WO2023149981A1
(en)
*
|
2022-02-07 |
2023-08-10 |
Purdue Research Foundation |
Compounds for the treatment of sars
|